Skip to main content

irbesartan

Generic: IRBESARTAN·Brand: AVAPRO, Avalide, Avapro, IRBESARTAN

irbesartan: 4 clinical trials tracked.

irbesartan evidence translation

What we can confirm

4 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about irbesartan, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (4)

A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy

NCT03762850Registry updated 2026-04-20·Phase 3·TVTX
Active, not recruiting

Primary endpoint: Percent Change From Baseline in the Urine Protein/Creatinine (UP/C) at Week 36

InterventionalRandomizedquadruple406 enrolledStarted 2018-12Completion 2026-0750 sites · Australia, United StatesTravere Therapeutics, Inc.

A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS

NCT03493685Registry updated 2026-04-17·Phase 3·TVTX
Completed

Primary endpoint: Slope of Estimated Glomerular Filtration Rate (eGFR)

InterventionalRandomizeddouble371 enrolledStarted 2018-04Completion 2026-0350 sites · United StatesTravere Therapeutics, Inc.

Efficacy and Safety of Sparsentan (RE-021), a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study

NCT01613118Registry updated 2025-05-15·Phase 2·TVTX
Completed

Primary endpoint: Percent Change in Urine Protein/Creatinine (Up/C)

InterventionalRandomizeddouble109 enrolledStarted 2014-03Completion 2024-0333 sites · Czechia, Italy, United StatesTravere Therapeutics, Inc.

Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C

NCT00265642Registry updated 2026-04-13·Phase 3
Completed

Primary endpoint: Assessment of liver fibrosis changes by measurement of area of porto-septal fibrosis (morphometry)at M24

InterventionalRandomizeddouble166 enrolledStarted 2006-10Completion 2013-111 site · FranceANRS, Emerging Infectious Diseases